Suggested Dosing
50-200 mg PO daily
CHF: 100 mg/day div BID-TID PO
Myocardial preservation for heart surgery: 200 mg/day PO
Suggested Uses
Angina, chronic fatigue syndrome, CHF, diabetes mellitus, doxorubicin-induced cardiotoxicity (prevention), HIV/AIDS immunostimulant, hypertension, mitochondrial cytopathies, muscular dystrophies, myopathy (statin-induced)
Efficacy may be effective in CHF, MI, mitochondrial encephalomyopathies
Reduces BP; more studies need before recommendation in hypertension
Inconclusive for stable angina, cardiomyopathy, periodontal disease
Huntington Disease (Orphan)
Orphan indication sponsors
- Integrative Therapeutics, Inc; 825 Challenger Drive; Green Bay , WI 54311
- Gel-Tec, Division of Tishcon Corp; 30 New York Avenue; PO Box 331; Westbury, NY 11590
Mitochondrial Cytopathies (Orphan)
Orphan indication sponsor
- Gel-Tec, Division of TISHCON Corporation; 30 New York Avenue; PO Box 331; Westbury, NY 11590
Pediatric Congestive Heart Failure (Orphan)
Orphan indication sponsor
- Gel-Tec, Division of TISHCON Corporation; 30 New York Avenue; PO Box 331; Westbury, NY 11590
Epidermolysis Bullosa (Orphan)
Orphan designation of ubidecarenone for treatment of epidermolysis bullosa
Sponsor
- Berg, LLC (BERG)l 500 Old Connecticut Path, Building B; Framingham, Massachusetts 01701
Interactions
Interaction Checker
No Results
Contraindicated
Serious - Use Alternative
Significant - Monitor Closely
Minor
Contraindicated (0)
Serious - Use Alternative (0)
Monitor Closely (1)
- warfarin
coenzyme Q10, warfarin. unspecified interaction mechanism. Use Caution/Monitor. The data from studies and case reports is conflicting.
Minor (16)
- atorvastatin
atorvastatin decreases levels of coenzyme Q10 by unspecified interaction mechanism. Minor/Significance Unknown.
- fluvastatin
fluvastatin decreases levels of coenzyme Q10 by unspecified interaction mechanism. Minor/Significance Unknown.
- glyburide
glyburide decreases levels of coenzyme Q10 by unspecified interaction mechanism. Minor/Significance Unknown.
- insulin aspart
coenzyme Q10 increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown. Monitor insulin requirements.
- insulin detemir
coenzyme Q10 increases effects of insulin detemir by pharmacodynamic synergism. Minor/Significance Unknown. Monitor insulin requirements.
- insulin glargine
coenzyme Q10 increases effects of insulin glargine by pharmacodynamic synergism. Minor/Significance Unknown. Monitor insulin requirements.
- insulin glulisine
coenzyme Q10 increases effects of insulin glulisine by pharmacodynamic synergism. Minor/Significance Unknown. Monitor insulin requirements.
- insulin lispro
coenzyme Q10 increases effects of insulin lispro by pharmacodynamic synergism. Minor/Significance Unknown. Monitor insulin requirements.
- insulin NPH
coenzyme Q10 increases effects of insulin NPH by pharmacodynamic synergism. Minor/Significance Unknown. Monitor insulin requirements.
- insulin regular human
coenzyme Q10 increases effects of insulin regular human by pharmacodynamic synergism. Minor/Significance Unknown. Monitor insulin requirements.
- lovastatin
lovastatin decreases levels of coenzyme Q10 by unspecified interaction mechanism. Minor/Significance Unknown.
- pitavastatin
pitavastatin decreases levels of coenzyme Q10 by unspecified interaction mechanism. Minor/Significance Unknown.
- pravastatin
pravastatin decreases levels of coenzyme Q10 by unspecified interaction mechanism. Minor/Significance Unknown.
- rosuvastatin
rosuvastatin decreases levels of coenzyme Q10 by unspecified interaction mechanism. Minor/Significance Unknown.
- simvastatin
simvastatin decreases levels of coenzyme Q10 by unspecified interaction mechanism. Minor/Significance Unknown.
- tolazamide
tolazamide decreases levels of coenzyme Q10 by unspecified interaction mechanism. Minor/Significance Unknown.
Adverse Effects
Frequency Not Defined
Diarrhea
Appetite decreased
Elevated LFTs
Gastric distress
Nausea
Warnings
Cautions
Biliary obstruction, concurrent antihypertensives, concurrent cancer chemotherapy, concurrent radiation therapy, hepatic insufficiency, hypertension
Pregnancy & Lactation
Pregnancy Category: N/A
Lactation: N/A
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available.Pharmacology
Metabolism: N/A
Excretion: N/A
Mechanism of Action
Ubiquinone: involved in electron transport chain
Ubiquinol: antioxidant, membrane stabilizer
